Concerning PI3K targeting, it has been generally accepted that the dual targeting of PI3K p110α and mTOR is the most potent strategy to inhibit the pathway in a variety of human cancers, including GBM, by circumventing some of the feedback loops which control tumor resistance to mTOR inhibitors [48]. The gene discussed is PIK3CB; the disease is cancer.